1. Experience of Harvesting Lymphocyte for CAR-T Cell Therapy in University Malaya Medical Centre During the COVID Pandemic.
- Author
-
Zakariah, Alia Zurina Md, Ahmad Makmom, Muhammad Amir Rasyid, Ganason, Gowri, and Lee Lai Ling, Christina
- Subjects
- *
COVID-19 pandemic , *CELLULAR therapy , *HARVESTING , *LYMPHOCYTES , *CHIMERIC antigen receptors - Abstract
Chimeric Antigen Receptor (CAR)-T cell therapy is a personalised immunotherapy where a patient's T cells are genetically modified to target cancer cells. This case study describes the first lymphocyte harvesting experience for CAR-T cell therapy, harvested at the University Malaya Medical Centre (UMMC) in Malaysia. Due to travel restrictions caused by COVID-19, patient was unable to travel abroad and hence the T cells were collected in UMMC and sent to a specialized facility in Singapore for genetic modification and expansion before being infused back into the patient. The study also discusses the limitations associated with CAR-T cell therapy, including production failures, scalability challenges, high costs, adverse events, vein to vein time, patient eligibility, and healthcare practitioner challenges. The conclusion highlights the financial viability and the importance of learning and improving CAR-T cell therapy for better patient care in Malaysia. [ABSTRACT FROM AUTHOR]
- Published
- 2023